期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

muc-1基因在非小细胞肺癌组织中的表达及临床意义

Expression of muc-1 gene in non-small cell lung cancer and its clinical significance
下载PDF
导出
摘要 目的:探讨muc-1基因在非小细胞肺癌(NSCLC)组织中的表达情况及其与淋巴结转移的相关性和临床意义。方法:应用RT-PCR方法检测36例NSCLC组织和10例正常肺组织中muc-1基因的表达情况。结果:36例NSCLC组织中有19例muc-1基因阳性表达,阳性表达率为52.7%,正常肺组织无muc-1表达。muc-1 mRNA在NSCLC组织中的阳性表达与患者的年龄、性别、组织学类型、病理分级、TNM分期及肿瘤大小无关(P>0.05),与淋巴结转移有关(χ2=6.733,P<0.05)。有淋巴结转移的NSCLC组织中muc-1基因阳性表达率高(N010%,N158.82%,N288.9%)。结论:muc-1基因阳性表达的NSCLC患者淋巴结转移率高,检测muc-1基因表达对NSCLC患者的预后和术后综合治疗具有指导性作用。 Objective To explore the relationship between expression of muc-1 gene in non-small cell lung cancer (NSCLC) tissues and lymph node metastasis and its clinical significance.Methods The expression of muc-1 gene in 36 specimens of NSCLC tissues and 10 normal lung tissues were determined by RT-PCR.Results muc-1 gene was positively expressed in 19 of 36 specimens of NSCLC tissues,the positive expression rate was 52.7%.The expression of muc-1 mRNA in NSCLC tissues was related to metastasis of lymph node(χ2 =6.73...
作者 李光虎 刘伟 付彤 刘国津
机构地区 吉林大学第一医院胸外科 吉林大学第一医院乳腺外科
出处 《吉林大学学报（医学版）》 CAS CSCD 北大核心 2008年第6期1046-1049,共4页 Journal of Jilin University：Medicine Edition
基金 中-加大学合作项目资助课题(SULCP010#)
关键词 癌 非小细胞肺 逆转录聚合酶链反应 MUC-1 carcinoma non-small cell lung RT-polymerase chain reaction muc-1
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1刘智鑫,刘国津.人非小细胞肺癌细胞药物敏感性检测及其与耐药因子p53抗体和GST-π表达的关系[J].吉林大学学报（医学版）,2005,31(5):795-798. 被引量：9
  • 2[3]Nagai S,Takenaka K,Sonobe M,et al.A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-smaU cell lung cancer[J].ThoracOncol,2006,1 (1):45-51.
  • 3[4]Musselli C,Ragupathi G,Gilew ski T,et al.Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1[J].Int J Cancer,2002,97 (5):660-667.
  • 4[5]Inata J,Hattori N,Yokoyama A,et al.Circulating KL-6/ MUC1 mucin carrying sialyl Lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma[J].IntJ Cancer,2007,120 (12):2643-2649.

二级参考文献12

  • 1William B, Williams D. Mechanisms of drug resistance [A].In: De Vita VT, Helman S, Rosenberg SA, eds. Cancer,principles & practice of oncology [M]. 5th Ed. Philadephia:Lippincott-Raven Publishers, 1997: 498-509.
  • 2Ettinger DS. Is there a preferred combination chemotherapy regimen for nonsmall cell lung cancer [J]. Oncologist, 2002,7 (3): 226-233.
  • 3Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay [J]. J Immunol Method , 1983, 65 (1-2): 55-63.
  • 4Parker SL, Tong T , Bolden S, et al. Cancer statistics [J].Cancer J Clin, 1996, 65: 5-27.
  • 5Harper JW, Adami GR, Wei N, et al. The p21 cdkinteracting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases [J]. Cell Biology, 1995, 75: 805-816.
  • 6Zwelling LA, Mayes J, Deisseroth K, et al. A restriction fragment length polymorphism for human topoisomerase Ⅱ:possible relationship to drug resistance [J]. Cancer Commun,1990, 2: 357-361.
  • 7Lai PBS, Ross JA, Fearon KCH, et al. Cell cycle arrest and induction of a poptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro [J]. Br J Cancer, 1996, 74:1375-1383.
  • 8Brambilla E, Brambilla C. p53 and lung cancer [J]. Pathol Biol, 1997, 45 (10): 852-863.
  • 9Lubin R, Schlichtholz B, Teilaud JL, et al. p53 antibodies in patients with various types of cancer assay, identification and characterization [J]. Clin Cancer Res, 1995, 1: 1463-1469.
  • 10Kawasaki M, Nakanishi Y, Kuwano K, et al. The utility of p53 of transbronchial biopsy specimens of lung cancer: p53overexpression predicts poor prognosis and chemoresistance in advance non-small cell lung cancer [J]. Clin Cancer Res,1997, 3 (7): 1195-2000.

共引文献8

吉林大学学报（医学版）
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部